Hematology

Last month, I headed to Denver with the rest of my DDN colleagues to attend the AACR's 100th Annual Meeting, eager to learn about the latest developments in oncology research. But during my last few hours in Denver, my bubble of optimism was pricked by deflating reality.

UCSC Cancer Genomics Browser uses ‘heatmaps’ to visually represent genomic and clinical data side by side

Millipore acquires Guava Technologies to further strengthen its position in the flow cytometry market

Duke and Johns Hopkins researchers discover genetic link to malignant glioma that could lead to better treatment for central nervous system cancers

ACD/Labs and Pharma Algorithms join forces to strengthen in silico screening and prediction

DURHAM, N.C.—Scientists at Duke University Medical Center and Johns Hopkins University have discovered mutations in two genes—isocitrate dehydrogenase 1, gene 1 and 2 (IDH1 and IDH2)—that could be important therapeutic targets for the class of brain tumors known as malignant glioma, and perhaps other central nervous system cancers as well.

Ariadne integrates Pathway Studio with Illumina’s GenomeStudio software

Working with four lymphoma patients whose bone marrow had been killed via chemotherapy, a team led by Dr. David DiGuisto, director of haematopoietic cell therapies at City of Hope Medical Center in Duarte, Calif., has demonstrated promising results from subsequent treatment with genetically altered stem cells. The scientists are planning further research to establish whether the treatment might rid patients of HIV infection altogether.

InforSense to provide translational research tools to British research center's mental health projects

There is an issue between students and professors that I've followed for a long time and been personally engaged in as a student, post-doc, professor and business leader. If a student/post-doc discovers something important using funding secured by the professor in an atmosphere provided by the professor, then how much credit should go to each?

Ensemble Discovery Corp. recently extended a collaboration with Roche that will deploy Ensemble’s diagnostic assays in human clinical studies to analyze combinations of epidermal growth factor receptors (EGFR) present in various cancer tissues.